Article
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.
Public health genomics - 1 Jan 2014
Brewer N T, Defrank J T, Chiu W K, Ibrahim J G, Walko C M, Rubin P, Olajide O A, Moore S G, Raab R E, Carrizosa D R, Corso S W, Schwartz G, Peppercorn J M, McLeod H L, Carey L A, Irvin W J
Abstract excerpt
BACKGROUND: CYP2D6 is a critical enzyme in the metabolism of tamoxifen and potentially a key determinant in breast cancer outcomes. Our study examined patients' beliefs about how the CYP2D6 genotype would affect their prognoses. METHODS: Women enrolled in a pharmacogenomic clinical trial and on tamoxifen for prevention or treatment of breast cancer underwent CYP2D6 genotyping (EM = extensive, IM = intermediate,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.